



Consolidated Financial Results for the Nine Months Ended September 30, 2025 (Under Japanese GAAP)

October 31, 2025

Company name CREATE MEDIC CO., LTD.
 Stock exchange listings : Tokyo Standard
 Securities code 5187
 URL <https://www.createmedic.co.jp/english/>
 Representative Osamu Imazawa President
 Inquiries Teruya Ueno Executive Officer, General Manager of Accounting Department
 Dividend payable date (as planned) : —
 Supplemental material of results : None
 Convening briefing of results : None

(Yen amounts are rounded down to millions, unless otherwise noted.)

1. Consolidated financial results for the nine months ended September 30, 2025 (from January 1, 2025 to September 30, 2025)

(1) Consolidated operating results (cumulative)

(Percentages indicate year-on-year changes.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent	
Nine months ended	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
September 30, 2025	10,054	5.7	913	75.3	871	59.9	666	(10.5)
September 30, 2024	9,512	3.8	521	(14.9)	545	(16.4)	744	—

Note: Comprehensive income For the nine months ended September 30, 2025 : 382 Millions of yen ((57.0)%)
 For the nine months ended September 30, 2024 : 891 Millions of yen (48.4%)

	Basic earnings per share	Diluted earnings per share
Nine months ended	Yen	Yen
September 30, 2025	78.45	76.57
September 30, 2024	83.85	—

(2) Consolidated financial position

	Total assets	Net assets	Capital adequacy ratio	Net assets per share
As of	Millions of yen	Millions of yen	%	Yen
September 30, 2025	19,151	15,623	81.6	1,863.14
December 31, 2024	20,047	15,750	78.6	1,833.67

Reference: Owner's equity As of September 30, 2025 15,622 Millions of yen
 As of December 31, 2024 15,750 Millions of yen

2. Cash dividends

	Annual dividend				
	First quarter	Second quarter	Third quarter	Year end	Annual
	Yen	Yen	Yen	Yen	Yen
Fiscal year ended December 31, 2024	—	19.00	—	20.00	39.00
Fiscal year ending December 31, 2025	—	17.00	—		
Fiscal year ending December 31, 2025 (Forecast)				20.00	37.00

Note: Revisions to the forecast of cash dividends most recently announced : None

3. Consolidated financial forecast for the fiscal year ending December 31, 2025 (from January 1, 2025 to December 31, 2025)

(Percentages indicate year-on-year changes.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent		Basic earnings per share
Fiscal year ending	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen
December 31, 2025	13,583	4.2	1,002	44.7	1,043	39.0	796	(5.3)	92.67

Note: Revisions to the earnings forecasts most recently announced : None

* Notes

(1) Significant changes in the scope of consolidation during the period : None

(2) Adoption of accounting treatment specific to the preparation of quarterly consolidated financial statements : None

(3) Changes in accounting policies, changes in accounting estimates, and restatement

(i) Changes in accounting policies due to revisions to accounting standards and other regulations : Yes

(ii) Changes in accounting policies due to other reasons : None

(iii) Changes in accounting estimates : None

(iv) Restatement : None

(4) Number of issued shares (common shares)

① Number of issued and outstanding shares at the period end (including treasury stock)

As of September 30, 2025	9,664,327shares	As of December 31, 2024	9,664,327shares
As of September 30, 2025	1,279,148shares	As of December 31, 2024	1,074,624shares
Nine months ended September 30, 2025	8,497,339shares	Nine months ended September 30, 2024	8,880,747shares

② Number of treasury stock at the period end

③ Average number of shares (quarterly period-YTD)

* Review of the Japanese-language originals of the attached consolidated quarterly financial statements by certified public accountants or an audit firm : None

* Proper use of earnings forecasts, and other special matters

Caution Regarding Forward-Looking Statements:

The forward-looking statements contained in this document are based on information currently available to the Company and certain assumptions that the Company deems to be reasonable. They are not intended as a promise by the Company that they will be achieved, and actual results may differ significantly due to various factors.